Article

Chronic hepatitis B virus infection and pancreatic cancer: a case-control study in southern China.

Department of Gastrointestinal and Pancreatic Surgery, the First Affiliated Hospital, Sun Yat-Sen University, China.
Asian Pacific journal of cancer prevention: APJCP (Impact Factor: 2.51). 01/2011; 12(6):1405-8.
Source: PubMed

ABSTRACT The association of hepatitis B virus (HBV) infection and pancreatic cancer is still controversial. The purpose of this study is to determine whether chronic HBV infection increases the risk.
In this case-control study, there were 1,066 patients recruited, with 533 in the study group and 533 controls, frequency-matched for age and sex. Blood samples were collected to detect hepatitis viral infection.
Compared to 77 patients (14.4%) in the control group, 80 pancreatic cancer patients (15.0%) were seropositive for HBV surface antigen (not statistically significant, P=0.8). The prevalence of HBV e antigen was higher in study group than that of control group (P=0.03). Further analysis indicated that HBeAg was a risk factor for pancreatic cancer (OR=2.935, 95% CI: 1.048-8.220).
In HBV endemic area of China, there appears to be no significant association between chronic HBV infection and pancreatic cancer, but the role of HBeAg needs further exploration.

Download full-text

Full-text

Available from: Haoran Li, Jan 06, 2014
0 Followers
 · 
113 Views
  • Source
    • "References Country or area Age (years) Study period Study design Control type PaC ascertainment Number of cases Number of control participants a HBV markers HBV detection NOS score Berrington de Gonzalez et al. (2008) Korea 45 + 1992–2005 Cohort NA Cancer registry; death certificates 2194 b 631 172 b HBsAg NS 6 Hassan et al. (2008) USA NS 2000–2007 Case–control P Pathologically 476 879 HBsAg, anti-HBs, anti-HBc ELISA 9 Iloeje et al. (2009) Taiwan 30–65 1991–2007 Cohort NA Cancer registry; death certification; national health insurance profiles 48 22 471 HBsAg, HBeAg c , HBV DNA Radioimmunoassay 9 Tang et al. (2009) USA 18 + 1995–2008 Retrospective cohort NA Cancer registry 101 74 851 HBsAg, anti-HBs, anti-HBc, HBeAg, HBV DNA NS 9 Chang et al. (2009) Taiwan NA NA Case–control P Cytological pathologically 147 1716 HBsAg, anti-HBs, anti-HBc — d — d Hong et al. (2010) Korea NS 2003–2008 Case–control H Histologically (58.1%) 506 1008 HBsAg anti-HBs, HBV DNA ARCHITECT assay 8 Wang et al. (2011) Mainland China NS 1999–2010 Case–control H Discharge diagnoses (histologically) 645 711 HBsAg, anti-HBs, anti-HBc, HBeAg, anti-HBe ELISA 8 Zhu et al. (2011) "
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: Whether hepatitis B virus (HBV) infection increases the risk of pancreatic cancer (PaC) is controversial. We carried out a meta-analysis to evaluate the association between HBV status and the risk of PaC. METHODS: PubMed, Embase, and the China National Knowledge Infrastructure were searched from their inception through April 2012 for case-control and cohort studies that have reported an association between HBV status and the risk of PaC. The reference lists of pertinent publications were also reviewed for potential studies. Methodological quality was assessed using the Newcastle-Ottawa Quality Assessment Scale. A random-effects model was used to summarize odd ratios (ORs) and 95% confidence intervals (CIs). RESULTS: We included seven case-control studies and three cohort studies, involving 5883 PaC cases. The summary OR of developing PaC was 1.22 (95% CI: 0.90-1.67) for individuals who were HBV surface antigen (HBsAg)-positive. Compared with the individuals who were never exposed to HBV infection, the summary OR of the risk of PaC was 1.60 (95% CI: 1.26-2.05) for chronic or inactive HBsAg carriers (HBsAg-positive) and 1.76 (95% CI: 1.05-2.93) for anti-HBc-positive but anti-HBs-negative individuals. CONCLUSION: Inactive HBsAg carrier status and possible occult HBV infection may increase the risk of PaC. Large population-based multicenter prospective studies are required to further confirm this finding.
    European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP) 11/2012; DOI:10.1097/CEJ.0b013e32835b6a21 · 2.76 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Hepatitis B virus (HBV) infection is reported to be associated with an increased risk of pancreatic cancer (PaC), but it remains controversial whether this is a causal relationship. In addition, it is unclear whether the status of HBV infection also affects PaC risk. Therefore, we conducted a meta-analysis to more closely examine the association between HBV infection and PaC. METHOD: The studies included in the meta-analysis were identified and retrieved from PubMed and several other databases. The literature search was conducted up until August 2012. We adopted the Cochrane Collaboration's RevMan 5.1 in a combined analysis of pooled relative risk (RR) with their corresponding 95 % confidence intervals (CIs) using a random-effects and a fixed-effects model. RESULTS: Nine studies including 6 case-control and 3 cohort studies met eligibility criteria. The meta-analysis showed that the PaC risk was positively correlated with HBV infection when comparing with 'never exposed to HBV' subgroup, the pooled RR was 1.39 (95 % CI 1.22-1.59, p < 0.00001) in chronic HBV carriers, 1.41 (95 % CI 1.06-1.87, p = 0.02) in past exposure to HBV, and 3.83 (95 % CI 1.76-8.36, p = 0.0007) in active HBV infection. Using a stratified analysis, we also found that the risk of PaC was independent of smoking, alcohol drinking, and diabetes. CONCLUSION: Findings from this meta-analysis strongly support that HBV infection is associated with an increased risk of PaC.
    Cancer Causes and Control 01/2013; 24(3). DOI:10.1007/s10552-012-0144-2 · 2.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Several studies have reported that ABO blood group, hepatitis B virus (HBV) and hepatitis C virus (HCV) infection contribute to the development of pancreatic cancer. The aim of this study was to evaluate the association between these factors and pancreatic cancer in the Korean population. We retrospectively recruited 753 patients with pancreatic cancer and 3,012 healthy controls, matched 4 to 1 with cancer patients for age and sex, between 2001 and 2011, at the National Cancer Center, Korea. A multivariate logistic regression analysis was employed to estimate adjusted odds ratios (AORs). The AOR for pancreatic cancer in subjects with non-O blood types (A, AB, and B), compared to blood type O, was 1.29 (95% CI, 1.05-1.58; P = 0.01). Seropositivity for hepatitis B virus surface antigen was not significantly related to pancreatic cancer, either in univariate (odds ratio 1.03; 95% CI, 0.69-1.53; P = 0.91) or multivariate analysis (AOR, 1.02; 95% CI, 0.67-1.56; P = 0.93). The AOR for pancreatic cancer in subjects displaying seropositivity for anti-HCV was 2.30 (95% CI, 1.30-4.08; P < 0.01). Our results suggest that the non-O blood types and anti-HCV seropositivity, but not HBV infection, may increase the risk of developing pancreatic cancer in Korea, where HBV is endemic.
    Journal of Korean medical science 02/2013; 28(2):247-51. DOI:10.3346/jkms.2013.28.2.247 · 1.25 Impact Factor